MSAA Reopens MRI Access Fund

The Multiple Sclerosis Associa …

Read News Article

Ibudilast Receives Fast Track Designation from FDA

MediciNova, Inc., the biopharmaceutical company developing ibudilast (MN-166), announced that this investigational medication for progressive forms of MS has received Fast Track designation from the United States Food and Drug Administration (FDA). This designation is intended for drugs under development for treating serious diseases and with the potential to address unmet medical needs for such diseases.

Read News Article

The Multiple Sclerosis Association of America to Ring the Nasdaq Opening Bell

The Multiple Sclerosis Association of America (MSAA) is honored to ring the Nasdaq Stock Market Opening Bell on Friday, March 11, 2016 at Nasdaq MarketSite in recognition of Multiple Sclerosis Awareness Month. MSAA President & CEO Gina Ross Murdoch will ring the bell to open the market accompanied by members of the MS community.

Read News Article

The Multiple Sclerosis Association of America Brings Awareness to Symptoms and Relapses during MS Awareness Month

The Multiple Sclerosis Association of America (MSAA) recognizes March as MS Awareness Month. For the more than 400,000 Americans living with multiple sclerosis (MS), the support of loved ones, care partners, and organizations such as MSAA are vital to improving their quality of life. MSAA’s Multiple Sclerosis Awareness Month campaign will devote each week in March to heightening the understanding of the management of relapses and multiple sclerosis symptoms.

Read News Article

The Multiple Sclerosis Association of America Launches Redesigned Website

The Multiple Sclerosis Association of America (MSAA) is pleased to announce the launch of the newly redesigned version of its website, mymsaa.org. The new www.mymsaa.org offers essential information and resources for the multiple sclerosis (MS) community in an easy-to-navigate, responsive-design format that is compatible with today’s browsers and mobile devices.

Read News Article